Compare Recursion Pharmaceuticals Inc (RXRX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B), while Verisign, Inc. trades at $305.75 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 12.6× Recursion Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Verisign, Inc. for 123 Days on average.
| RXRX | VRSN | |
|---|---|---|
Market Cap | $2.14B | $26.92B |
Volume | 30,789,535 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $6.79 | $310.00 |
52-Week Low | $2.84 | $211.49 |
Typical Hold Time | 22 Days | 123 Days |
Enterprise Value | $1.66B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
VeriSign (VRSN) trades at $301.59, up 2.5% today, with a bullish technical signal and strong institutional buying. The company reported robust Q2 2026 earnings with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations. High profitability is evident with a net income margin near 50%, and cash flow trends are improving. Recent news includes a class-action antitrust lawsuit and insider selling by the CEO, but analyst consensus remains positive.
The outlook is supported by solid fundamentals and a consensus price target of $348, offering ~15% upside. Key risks include legal challenges from the antitrust suit and reliance on domain registration growth. Earnings momentum and institutional accumulation provide tailwinds, but investors should weigh litigation risks against the company's stable cash flows and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
